CA3188639A1 - Tricyclic urea compounds as jak2 v617f inhibitors - Google Patents

Tricyclic urea compounds as jak2 v617f inhibitors

Info

Publication number
CA3188639A1
CA3188639A1 CA3188639A CA3188639A CA3188639A1 CA 3188639 A1 CA3188639 A1 CA 3188639A1 CA 3188639 A CA3188639 A CA 3188639A CA 3188639 A CA3188639 A CA 3188639A CA 3188639 A1 CA3188639 A1 CA 3188639A1
Authority
CA
Canada
Prior art keywords
alkyl
cycloalkyl
membered
membered heterocycloalkyl
independently selected
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3188639A
Other languages
English (en)
French (fr)
Inventor
Yanran AI
Onur Atasoylu
Yu Bai
Joseph Barbosa
David M. Burns
Daniel Levy
Brent Douty
Hao Feng
Leah C. Konkol
Cheng-Tsung Lai
Xun Liu
Song MEI
Jun Pan
Haisheng Wang
Liangxing Wu
Wenqing Yao
Eddy W. Yue
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Incyte Corp
Original Assignee
Incyte Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Incyte Corp filed Critical Incyte Corp
Publication of CA3188639A1 publication Critical patent/CA3188639A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D521/00—Heterocyclic compounds containing unspecified hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
CA3188639A 2020-07-02 2021-07-01 Tricyclic urea compounds as jak2 v617f inhibitors Pending CA3188639A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202063047483P 2020-07-02 2020-07-02
US63/047,483 2020-07-02
US202163164302P 2021-03-22 2021-03-22
US63/164,302 2021-03-22
PCT/US2021/040185 WO2022006457A1 (en) 2020-07-02 2021-07-01 Tricyclic urea compounds as jak2 v617f inhibitors

Publications (1)

Publication Number Publication Date
CA3188639A1 true CA3188639A1 (en) 2022-01-06

Family

ID=77104160

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3188639A Pending CA3188639A1 (en) 2020-07-02 2021-07-01 Tricyclic urea compounds as jak2 v617f inhibitors

Country Status (29)

Country Link
US (3) US11780840B2 (enExample)
EP (2) EP4175719B1 (enExample)
JP (1) JP7848174B2 (enExample)
KR (1) KR20230057341A (enExample)
CN (1) CN116323612A (enExample)
AU (1) AU2021300429A1 (enExample)
BR (1) BR112023000047A2 (enExample)
CA (1) CA3188639A1 (enExample)
CL (1) CL2022003834A1 (enExample)
CO (1) CO2023001165A2 (enExample)
CR (1) CR20230057A (enExample)
DK (1) DK4175719T3 (enExample)
EC (1) ECSP23007180A (enExample)
ES (1) ES3035284T3 (enExample)
FI (1) FI4175719T3 (enExample)
HR (1) HRP20250814T1 (enExample)
HU (1) HUE072186T2 (enExample)
IL (1) IL299612A (enExample)
LT (1) LT4175719T (enExample)
MA (1) MA60209B1 (enExample)
MD (1) MD4175719T2 (enExample)
MX (1) MX2023000056A (enExample)
PE (1) PE20231739A1 (enExample)
PL (1) PL4175719T3 (enExample)
PT (1) PT4175719T (enExample)
RS (1) RS66978B1 (enExample)
SI (1) SI4175719T1 (enExample)
SM (1) SMT202500271T1 (enExample)
WO (1) WO2022006457A1 (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021257863A1 (en) 2020-06-19 2021-12-23 Incyte Corporation Pyrrolotriazine compounds as jak2 v617f inhibitors
US11691971B2 (en) 2020-06-19 2023-07-04 Incyte Corporation Naphthyridinone compounds as JAK2 V617F inhibitors
US11767323B2 (en) 2020-07-02 2023-09-26 Incyte Corporation Tricyclic pyridone compounds as JAK2 V617F inhibitors
CR20230057A (es) 2020-07-02 2023-08-15 Incyte Corp Compuestos tríciclicos de urea como inhibidores de jak2 v617f
US11661422B2 (en) 2020-08-27 2023-05-30 Incyte Corporation Tricyclic urea compounds as JAK2 V617F inhibitors
US11919908B2 (en) 2020-12-21 2024-03-05 Incyte Corporation Substituted pyrrolo[2,3-d]pyrimidine compounds as JAK2 V617F inhibitors
AR125273A1 (es) 2021-02-25 2023-07-05 Incyte Corp Lactamas espirocíclicas como inhibidores de jak2 v617f
AU2023235313A1 (en) 2022-03-17 2024-10-03 Incyte Corporation Tricyclic urea compounds as jak2 v617f inhibitors
CN115403581B (zh) * 2022-07-18 2023-03-28 英矽智能科技(上海)有限公司 作为irak4抑制剂的杂环化合物
TW202408495A (zh) * 2022-08-25 2024-03-01 大陸商啟元生物（杭州）有限公司 Jak激酶抑制劑的前藥
US20240190876A1 (en) 2022-10-21 2024-06-13 Incyte Corporation Tricyclic Urea Compounds As JAK2 V617F Inhibitors
JP2026509874A (ja) * 2023-03-13 2026-03-25 インサイト・コーポレイション キナーゼ阻害剤としての二環式尿素
TW202540121A (zh) * 2023-11-22 2025-10-16 美商雷瑟拉股份有限公司 Jak2 v617f抑制劑及其使用方法
WO2025245175A1 (en) * 2024-05-22 2025-11-27 Ajax Therapeutics, Inc. Macrocyclic heteroaromatic inhibitors of jak2
US20260078131A1 (en) * 2024-09-06 2026-03-19 Ajax Therapeutics, Inc. Pyrrolo-pyridazine inhibitors of jak2

Family Cites Families (287)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4698341A (en) 1983-07-30 1987-10-06 Godecke Aktiengesellschaft Use of 1,6-naphthyridinone derivatives in treating pulmonary thrombosis
JPS62209062A (ja) 1986-03-10 1987-09-14 Yamanouchi Pharmaceut Co Ltd ２−ピリジルメチルチオ−または２−ピリジルメチルスルフイニル−置換縮合環化合物
DE3804990A1 (de) 1988-02-18 1989-08-31 Basf Ag Herbizid wirksame, heterocyclisch substituierte sulfonamide
CA2053148A1 (en) 1990-10-16 1992-04-17 Karnail Atwal Dihydropyrimidine derivatives
US5326776A (en) 1992-03-02 1994-07-05 Abbott Laboratories Angiotensin II receptor antagonists
WO1993017682A1 (en) 1992-03-04 1993-09-16 Abbott Laboratories Angiotensin ii receptor antagonists
JPH0789957A (ja) 1993-09-22 1995-04-04 Nissan Chem Ind Ltd ビフェニルメチルアミン誘導体
TW263498B (enExample) 1993-11-10 1995-11-21 Takeda Pharm Industry Co Ltd
DE4344452A1 (de) 1993-12-24 1995-06-29 Hoechst Ag Aza-4-iminochinoline, Verfahren zu ihrer Herstellung und ihre Verwendung
AR006520A1 (es) 1996-03-20 1999-09-08 Astra Pharma Prod Derivados de 2-arilpirazolisoquinolina y cinolinona y procedimiento para su preparacion.
WO1997047601A1 (en) 1996-06-11 1997-12-18 Yoshitomi Pharmaceutical Industries, Ltd. Fused heterocyclic compounds and medicinal uses thereof
BR9714349A (pt) 1996-10-16 2000-11-14 Icn Pharmaceuticals L-nucleosìdeos purina, seus análogos e utilizacões dos mesmos
US6177464B1 (en) 1997-03-14 2001-01-23 Sepracor, Inc. Ring opening metathesis of alkenes
US6339099B1 (en) 1997-06-20 2002-01-15 Dupont Pharmaceuticals Company Guanidine mimics as factor Xa inhibitors
TR200003429T2 (tr) 1998-05-26 2001-07-23 Warner-Lambert Company Hücresel çoğalma inhibitörleri olarak bisiklik pirimidinler ve bisiklik 3,4-dihidropirimidinler.
JP2002517486A (ja) 1998-06-12 2002-06-18 バーテックス ファーマシューティカルズ インコーポレイテッド ｐ３８のインヒビター
JP2000123973A (ja) 1998-10-09 2000-04-28 Canon Inc 有機発光素子
DE19900545A1 (de) 1999-01-11 2000-07-13 Basf Ag Verwendung von Pyrimidinderivaten zur Prophylaxe und Therapie der zerebralen Ischämie
WO2000068230A1 (en) 1999-05-05 2000-11-16 Darwin Discovery Limited 9-(1,2,3,4-tetrahydronaphthalen-1-yl)-1,9-dihydropurin-6-one derivatives as pde7 inhibitors
US6417207B1 (en) 1999-05-12 2002-07-09 Nitromed, Inc. Nitrosated and nitrosylated potassium channel activators, compositions and methods of use
PL354784A1 (en) 1999-09-30 2004-02-23 Neurogen Corporation Certain alkylene diamine-substituted heterocycles
TWI271406B (en) 1999-12-13 2007-01-21 Eisai Co Ltd Tricyclic condensed heterocyclic compounds, preparation method of the same and pharmaceuticals comprising the same
US6787534B2 (en) 1999-12-28 2004-09-07 Eisai Co., Ltd. Sulfonamide-containing heterocyclic compounds
PT1254138E (pt) 2000-02-09 2005-09-30 Novartis Ag Derivados de piridina que inibem a angiogenese e/ou o receptor de tirosina cinase do vegf
CA2403558A1 (en) 2000-03-23 2001-09-27 Merck & Co., Inc. Thrombin inhibitors
KR100786927B1 (ko) 2000-06-28 2007-12-17 스미스클라인비이참피이엘시이 습식 분쇄방법
JP2004529943A (ja) 2001-05-15 2004-09-30 イー・アイ・デュポン・ドウ・ヌムール・アンド・カンパニー 殺菌・殺カビ剤としてのピリジニル縮合二環式アミド
US20030139431A1 (en) 2001-09-24 2003-07-24 Kawakami Joel K. Guanidines which are agonist/antagonist ligands for neuropeptide FF (NPFF) receptors
JP2003107641A (ja) 2001-09-27 2003-04-09 Fuji Photo Film Co Ltd ハロゲン化銀感光材料
HUP0500200A2 (hu) 2002-01-17 2005-07-28 Neurogen Corporation Szubsztituált kinazolin-4-ilamin analógok, mint kapszaicin modulátorok és ezeket tartalmazó gyógyszerkészítmények
JP4542783B2 (ja) 2002-03-05 2010-09-15 エーザイ・アール・アンド・ディー・マネジメント株式会社 スルホンアミド含有複素環化合物及び血管新生抑制剤とを組み合わせてなる抗腫瘍剤
ATE404537T1 (de) 2002-08-13 2008-08-15 Shionogi & Co Heterocyclische verbindungen mit hiv-integrase- hemmender wirkung
BR0313724A (pt) 2002-08-13 2005-06-28 Warner Lambert Co Derivados de azaisoquinolina como inibidores de metaloproteinase de matriz
AU2003282726B2 (en) 2002-10-03 2010-10-07 Targegen, Inc. Vasculostatic agents and methods of use thereof
JP4690043B2 (ja) 2002-10-04 2011-06-01 プラナ バイオテクノロジー リミティッド 神経に対し活性な化合物
AU2003280578A1 (en) 2002-10-30 2004-05-25 Ajinomoto Co., Inc. Heterocyclic compounds
EP1569925A1 (en) 2002-12-13 2005-09-07 Neurogen Corporation 2-substituted quinazolin-4-ylamine analogues as capsaicin receptor modulators
JP2004196702A (ja) 2002-12-18 2004-07-15 Yamanouchi Pharmaceut Co Ltd 新規なアミド誘導体又はその塩
CA2518398A1 (en) 2003-03-10 2004-09-23 Schering Corporation Heterocyclic kinase inhibitors: methods of use and synthesis
JP2006522814A (ja) 2003-04-11 2006-10-05 タイゲン・バイオテクノロジー アミノキノリン化合物
WO2006074147A2 (en) 2005-01-03 2006-07-13 Myriad Genetics, Inc. Nitrogen containing bicyclic compounds and therapeutical use thereof
AU2004253967B2 (en) 2003-07-03 2010-02-18 Cytovia, Inc. 4-arylamino-quinazolines as activators of caspases and inducers of apoptosis
RS20060018A (sr) 2003-07-14 2007-12-31 Arena Pharmaceuticals Inc., Derivati spojenih arila i heteroarila kao modulatori metabolizma u profilaksi i lečenju sa njima povezanih stanja
EP1660087A2 (en) 2003-07-22 2006-05-31 Janssen Pharmaceutica N.V. Quinolinone derivatives as inhibitors of c-fms kinase
CA2537325A1 (en) 2003-09-19 2005-03-31 Gilead Sciences, Inc. Aza-quinolinol phosphonate integrase inhibitor compounds
US20060004043A1 (en) 2003-11-19 2006-01-05 Bhagwat Shripad S Indazole compounds and methods of use thereof
EP1692112A4 (en) 2003-12-08 2008-09-24 Cytokinetics Inc COMPOUNDS, COMPOSITIONS, AND METHODS
CA2553670A1 (en) 2004-01-29 2005-08-11 Elixir Pharmaceuticals, Inc. Anti-viral therapeutics
US20050182060A1 (en) 2004-02-13 2005-08-18 Kelly Michael G. 2-Substituted and 4-substituted aryl nitrone compounds
GB0403635D0 (en) 2004-02-18 2004-03-24 Devgen Nv Pyridinocarboxamides with improved activity as kinase inhibitors
WO2005080377A1 (ja) 2004-02-20 2005-09-01 Kirin Beer Kabushiki Kaisha TGFβ阻害活性を有する化合物およびそれを含んでなる医薬組成物
WO2005112932A2 (en) 2004-05-07 2005-12-01 Exelixis, Inc. Raf modulators and methods of use
WO2005110410A2 (en) 2004-05-14 2005-11-24 Abbott Laboratories Kinase inhibitors as therapeutic agents
WO2005121138A2 (en) 2004-06-03 2005-12-22 Rigel Pharmaceuticals, Inc. Heterotricyclic compounds for use as hcv inhibitors
GB0412467D0 (en) 2004-06-04 2004-07-07 Astrazeneca Ab Chemical compounds
DE102004041163A1 (de) 2004-08-25 2006-03-02 Morphochem Aktiengesellschaft für kombinatorische Chemie Neue Verbindungen mit antibakterieller Aktivität
GB0420970D0 (en) 2004-09-21 2004-10-20 Smithkline Beecham Corp Novel triazoloquinoline compounds
US20070054916A1 (en) 2004-10-01 2007-03-08 Amgen Inc. Aryl nitrogen-containing bicyclic compounds and methods of use
WO2006045010A2 (en) 2004-10-20 2006-04-27 Resverlogix Corp. Stilbenes and chalcones for the prevention and treatment of cardiovascular diseases
FR2877013A1 (fr) 2004-10-27 2006-04-28 Assist Publ Hopitaux De Paris Indentification d'une mutation de jak2 impliquee dans la polyglobulie de vaquez
WO2006065842A2 (en) 2004-12-13 2006-06-22 Synta Pharmaceuticals Corp. 5,6,7,8-tetrahydroquinolines and related compounds and uses thereof
KR100896380B1 (ko) 2005-01-07 2009-05-08 화이자 프로덕츠 인코포레이티드 헤테로방향족 퀴놀린 화합물 및 ｐｄｅ10 저해제로서의그의 용도
RU2007140733A (ru) 2005-04-06 2009-05-20 Айрм Ллк (Bm) Диариламинсодержащие соединения и композиции, и их применение в качестве модуляторов ядерных рецепторов стероидного гормона
EP2392328A1 (en) 2005-05-09 2011-12-07 Hydra Biosciences, Inc. Compounds for modulating TRPV3 Function
WO2007002781A2 (en) 2005-06-28 2007-01-04 Bausch & Lomb Incorporated Preparations comprising arylazine substituted with a carbonylic moiety to increase the activity of gelatinase a in ocular cells
CN102127078A (zh) 2005-07-14 2011-07-20 安斯泰来制药株式会社 Janus激酶3的杂环类抑制剂
WO2007007919A2 (en) 2005-07-14 2007-01-18 Astellas Pharma Inc. Heterocyclic janus kinase 3 inhibitors
US8410109B2 (en) 2005-07-29 2013-04-02 Resverlogix Corp. Pharmaceutical compositions for the prevention and treatment of complex diseases and their delivery by insertable medical devices
WO2007022946A1 (de) 2005-08-21 2007-03-01 Abbott Gmbh & Co. Kg Heterocyclische verbindungen und ihre verwendung als bindungspartner für 5-ht5-rezeptoren
MX2008002731A (es) 2005-09-01 2008-03-26 Hoffmann La Roche Diaminopirimidinas como moduladores de p2x3 y p3x2/3.
US7482360B2 (en) 2005-09-23 2009-01-27 Schering Corporation Fused tetracyclic mGluR1 antagonists as therapeutic agents
WO2007047653A2 (en) 2005-10-17 2007-04-26 Sloan-Kettering Institute For Cancer Research Synthetic hla binding peptide analogues of mutant v617f jak2 enzyme and uses therefor
WO2007051062A2 (en) 2005-10-28 2007-05-03 Chemocentryx, Inc. Substituted dihydropyridines and methods of use
US7989461B2 (en) 2005-12-23 2011-08-02 Amgen Inc. Substituted quinazolinamine compounds for the treatment of cancer
WO2007082131A1 (en) 2006-01-09 2007-07-19 Bristol-Myers Squibb Company Process for the preparation of hydroxy substituted heterocycles
WO2007112347A1 (en) 2006-03-28 2007-10-04 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
EP2010505B1 (en) 2006-03-28 2012-12-05 Atir Holding S.A. Heterocyclic compounds and uses thereof in the treatment of sexual disorders
WO2007113565A1 (en) 2006-04-06 2007-10-11 Astrazeneca Ab Naphthyridine derivatives as anti-cancer agents
CA2651072A1 (en) 2006-05-01 2007-11-08 Pfizer Products Inc. Substituted 2-amino-fused heterocyclic compounds
JP2009536657A (ja) 2006-05-10 2009-10-15 レノビス， インコーポレイテッド イオンチャンネルリガンドとしてのアミド誘導体およびそれを用いる医薬組成物および方法
MX2008014618A (es) 2006-05-15 2008-11-28 Irm Llc Composiciones y metodos para inhibidores de cinasas del receptor fgf.
TWI398252B (zh) 2006-05-26 2013-06-11 諾華公司 吡咯并嘧啶化合物及其用途
US8163760B2 (en) 2006-06-22 2012-04-24 Prana Biotechnology Limited Use of pyridopyrimidine compounds in the treatment of gliomas
CA2656150A1 (en) 2006-06-28 2008-01-03 Sanofi-Aventis New cxcr2 inhibitors
CA2655720A1 (en) 2006-06-29 2008-01-10 Schering Corporation Substituted bicyclic and tricyclic thrombin receptor antagonists
HRP20140688T1 (hr) 2006-07-07 2014-10-24 Bristol-Myers Squibb Company Inhibitori piroltriazin kinaze
GB0614052D0 (en) 2006-07-14 2006-08-23 Amura Therapeutics Ltd Compounds
DE602007006835D1 (de) 2006-07-20 2010-07-08 Amgen Inc Substituierte pyridonverbindungen und anwendungsverfahren
US20080021013A1 (en) 2006-07-21 2008-01-24 Cephalon, Inc. JAK inhibitors for treatment of myeloproliferative disorders
US7531539B2 (en) 2006-08-09 2009-05-12 Bristol-Myers Squibb Company Pyrrolotriazine kinase inhibitors
PL2383297T3 (pl) 2006-08-14 2013-06-28 Xencor Inc Zoptymalizowane przeciwciała ukierunkowane na CD19
CA2661436A1 (en) 2006-08-24 2008-02-28 Serenex, Inc. Isoquinoline, quinazoline and phthalazine derivatives
CN101573352A (zh) 2006-10-21 2009-11-04 艾博特股份有限两合公司 杂环化合物和其作为糖原合酶激酶3抑制剂的用途
KR100789731B1 (ko) 2006-11-15 2008-01-03 전남대학교산학협력단 파이로시퀀싱을 이용한 ｊａｋ2 ｖ617ｆ 돌연변이의 정량적검출방법, 시발체 및 키트
JP2010510317A (ja) 2006-11-20 2010-04-02 ブリストル−マイヤーズ スクイブ カンパニー ジペプチジルペプチダーゼｉｖの阻害剤としての７，８−ジヒドロ−１，６−ナフチリジン−５（６ｈ）−オンおよび関連二環式化合物、および方法
CA2673038C (en) 2006-12-22 2015-12-15 Incyte Corporation Substituted tricyclic heteroaryl compounds as janus kinase inhibitors
AR064879A1 (es) 2007-01-12 2009-04-29 Astellas Pharma Inc Compuesto de piridina condensado
PT2118074E (pt) 2007-02-01 2014-03-20 Resverlogix Corp Compostos para a prevenção e tratamento de doenças cardiovasculares
WO2008112217A1 (en) 2007-03-13 2008-09-18 Merck & Co., Inc. Inhibitors of janus kinases and/or 3-phosphoinositide-dependent protein kinase-1
EP1972627A1 (en) 2007-03-19 2008-09-24 Technische Universität Carolo-Wilhelmina zu Braunschweig Amino-napthyridine derivatives
US7776857B2 (en) 2007-04-05 2010-08-17 Amgen Inc. Aurora kinase modulators and method of use
US8039505B2 (en) 2007-04-11 2011-10-18 University Of Utah Research Foundation Compounds for modulating T-cells
WO2008135524A2 (en) 2007-05-02 2008-11-13 Boehringer Ingelheim International Gmbh Substituted anthranilamides and analogues, manufacturing and use thereof as medicaments
CN101679357A (zh) 2007-05-09 2010-03-24 辉瑞大药厂 取代的杂环衍生物及其组合物和作为抗菌剂的药物用途
KR20100033981A (ko) 2007-06-03 2010-03-31 벤더르빌트 유니버시티 벤즈아미드 대사성 글루타민산염 수용체5 양성 알로스테릭 조절자 및 이의 제조 및 사용방법
US9321730B2 (en) 2007-08-21 2016-04-26 The Hong Kong Polytechnic University Method of making and administering quinoline derivatives as anti-cancer agents
CN104119310B (zh) 2007-09-26 2017-04-12 约翰斯霍普金斯大学 作为新的在生理学上可用于硝酰基供体的n‑羟基磺酰胺衍生物及包含其的医药组合物
HUE029767T2 (en) 2008-03-11 2017-04-28 Incyte Holdings Corp JAK inhibitor azetidine and cyclobutane derivatives
WO2009146034A2 (en) 2008-03-31 2009-12-03 Takeda Pharmaceutical Company Limited Mapk/erk kinase inhibitors and methods of use thereof
WO2010002472A1 (en) 2008-07-02 2010-01-07 Ambit Biosciences Corporation Jak kinase modulating compounds and methods of use thereof
EP2318410A2 (en) 2008-07-09 2011-05-11 Envivo Pharmaceuticals, Inc. New small-molecule pde-10 inhibitors
WO2010026771A1 (ja) 2008-09-08 2010-03-11 日本曹達株式会社 含窒素ヘテロ環化合物およびその塩並びに農園芸用殺菌剤
ES2542884T3 (es) 2008-09-23 2015-08-12 Rigel Pharmaceuticals, Inc. Inhibidores de JAK de carbamato tricíclico
CN102245610B (zh) 2008-10-08 2014-04-30 百时美施贵宝公司 吡咯并三嗪激酶抑制剂
US20130190309A1 (en) 2008-12-16 2013-07-25 Chi B. Vu Phthalazinone and related analogs as sirtuin modulators
AR074760A1 (es) 2008-12-18 2011-02-09 Metabolex Inc Agonistas del receptor gpr120 y usos de los mismos en medicamentos para el tratamiento de diabetes y el sindrome metabolico.
US8546405B2 (en) 2008-12-23 2013-10-01 Abbott Laboratories Anti-viral compounds
BRPI0923796A2 (pt) 2008-12-29 2018-05-29 Southern Research Institute compostos antivirais, tratamento e ensaio
AU2010221417A1 (en) 2009-03-02 2011-09-22 Sirtris Pharmaceuticals, Inc. 8-substituted quinolines and related analogs as sirtuin modulators
KR101913109B1 (ko) 2009-03-18 2018-10-31 리스버로직스 코퍼레이션 신규한 소염제
WO2010107768A1 (en) 2009-03-18 2010-09-23 Schering Corporation Bicyclic compounds as inhibitors of diacylglycerol acyltransferase
US8691187B2 (en) 2009-03-23 2014-04-08 Eli Lilly And Company Imaging agents for detecting neurological disorders
JP2012521988A (ja) 2009-03-23 2012-09-20 シーメンス メディカル ソリューションズ ユーエスエー インコーポレイテッド 神経学的障害を検知するためのイメージング剤
US9757368B2 (en) 2009-04-22 2017-09-12 Resverlogix Corp. Anti-inflammatory agents
GB0907551D0 (en) 2009-05-01 2009-06-10 Univ Dundee Treatment or prophylaxis of proliferative conditions
JP5789252B2 (ja) 2009-05-07 2015-10-07 インテリカイン， エルエルシー 複素環式化合物およびその使用
WO2010141062A1 (en) 2009-06-04 2010-12-09 Ludwig Institute For Cancer Research Ltd. Inhibitors of constitutively active janus kinases and uses thereof
SI2440547T1 (sl) 2009-06-12 2023-05-31 Abivax Nove kemične molekule, ki zavirajo mehanizem spajanja za zdravljenje bolezni, ki so posledica napak pri spajanju
US10253020B2 (en) 2009-06-12 2019-04-09 Abivax Compounds for preventing, inhibiting, or treating cancer, AIDS and/or premature aging
WO2011004276A1 (en) 2009-07-06 2011-01-13 Pfizer Limited Hepatitis c virus inhibitors
NZ598220A (en) 2009-08-17 2014-02-28 Intellikine Llc Heterocyclic compounds and uses thereof
MX2012002480A (es) * 2009-09-03 2012-03-26 Bristol Myers Squibb Co Inhibidores de jak2 y su uso en el tratamiento de enfermedades mieloproliferativas y cancer.
KR101097315B1 (ko) 2009-10-12 2011-12-23 삼성모바일디스플레이주식회사 유기 발광 소자
CN102574843B (zh) 2009-10-22 2015-06-17 法博太科制药有限公司 抗纤维化剂的稠环类似物
WO2011050245A1 (en) 2009-10-23 2011-04-28 Yangbo Feng Bicyclic heteroaryls as kinase inhibitors
MX2012004846A (es) 2009-10-29 2012-10-05 Genosco Inhibidores de cinasa.
PH12012501000A1 (en) 2009-12-01 2013-02-11 Abbvie Inc Novel tricyclic compounds
CA2781888C (en) 2009-12-11 2019-06-18 Nono Inc. Agents and methods for treating ischemic and other diseases
TW201130842A (en) 2009-12-18 2011-09-16 Incyte Corp Substituted fused aryl and heteroaryl derivatives as PI3K inhibitors
WO2011078143A1 (ja) 2009-12-22 2011-06-30 塩野義製薬株式会社 ピリミジン誘導体およびそれらを含有する医薬組成物
EP2518064A1 (en) 2009-12-25 2012-10-31 Mochida Pharmaceutical Co., Ltd. Novel aryl urea derivative
RU2012132278A (ru) 2010-01-12 2014-02-20 Ф. Хоффманн-Ля Рош Аг Трициклические гетероциклические соединения, содержащие их композиции и способы их применения
CA2789344A1 (en) 2010-02-15 2011-08-18 Jeremy Earle Wulff Synthesis of bicyclic compounds and method for their use as therapeutic agents
WO2011103557A1 (en) 2010-02-22 2011-08-25 Advanced Cancer Therapeutics, Llc Small molecule inhibitors of pfkfb3 and glycolytic flux and their methods of use as anti-cancer therapeutics
US20110237599A1 (en) 2010-03-10 2011-09-29 Kalypsys, Inc. Heterocyclic inhibitors of histamine receptors for the treatment of disease
RU2605549C2 (ru) 2010-04-02 2016-12-20 Синомикс, Инк. Производные 3-карбокси-4-аминохинолина, полезные как модификаторы сладкого вкуса
WO2011137428A1 (en) 2010-04-30 2011-11-03 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods of treating hiv infection: inhibition of dna dependent protein kinase
CA2799579A1 (en) 2010-05-21 2011-11-24 Intellikine, Inc. Chemical compounds, compositions and methods for kinase modulation
US8299117B2 (en) 2010-06-16 2012-10-30 Metabolex Inc. GPR120 receptor agonists and uses thereof
HRP20160305T1 (hr) 2010-10-26 2016-07-01 Mars, Incorporated Borati kao inhibitori arginaze
JP2013541591A (ja) 2010-11-04 2013-11-14 アムジエン・インコーポレーテツド 複素環化合物およびそれらの使用
KR101817221B1 (ko) 2010-11-18 2018-01-10 카시나 라일라 이노바 파마슈티칼스 프라이빗 리미티드 치환된 4-(셀레노펜-2(또는 3)-일아미노)피리미딘 화합물 및 이의 사용방법
WO2012078902A2 (en) 2010-12-08 2012-06-14 Proteostasis Therapeutics, Inc. Proteostasis regulators
WO2012083866A1 (en) 2010-12-22 2012-06-28 The Hong Kong Polytechnic University Quinoline derivatives as anti-cancer agents
WO2012085176A1 (en) 2010-12-23 2012-06-28 F. Hoffmann-La Roche Ag Tricyclic pyrazinone compounds, compositions and methods of use thereof as janus kinase inhibitors
US9090592B2 (en) 2010-12-30 2015-07-28 AbbVie Deutschland GmbH & Co. KG Heterocyclic compounds and their use as glycogen synthase kinase-3 inhibitors
WO2012097479A1 (en) 2011-01-21 2012-07-26 Abbott Laboratories Bicyclic inhibitors of anaphastic lymphoma kinase
US20120214842A1 (en) 2011-02-18 2012-08-23 Exonhit Therapeutics Sa Methods for treating diseases of the retina
WO2012116237A2 (en) 2011-02-23 2012-08-30 Intellikine, Llc Heterocyclic compounds and uses thereof
CN103547580B (zh) 2011-03-22 2016-12-07 阿迪维纳斯疗法有限公司 取代的稠合三环化合物、其组合物及医药用途
US9433219B2 (en) 2011-04-20 2016-09-06 The Regents Of The University Of California Fungi antagonistic to xylella fastidiosa
CN102838600A (zh) 2011-06-24 2012-12-26 山东亨利医药科技有限责任公司 苯基喹唑啉类PI3Kδ抑制剂
CN102838601A (zh) 2011-06-24 2012-12-26 山东亨利医药科技有限责任公司 选择性磷酰肌醇3-激酶δ抑制剂
WO2013007765A1 (en) 2011-07-13 2013-01-17 F. Hoffmann-La Roche Ag Fused tricyclic compounds for use as inhibitors of janus kinases
WO2013033093A1 (en) 2011-08-29 2013-03-07 Biocryst Pharmaceuticals, Inc. Heterocyclic compounds as janus kinase inhibitors
MX2014002542A (es) 2011-08-29 2014-07-09 Infinity Pharmaceuticals Inc Compuestos heterociclicos y usos de los mismos.
WO2013033268A2 (en) 2011-08-29 2013-03-07 Coferon, Inc. Bivalent bromodomain ligands, and methods of using same
WO2013033981A1 (zh) 2011-09-06 2013-03-14 江苏先声药物研究有限公司 一类2,7-萘啶衍生物及其制备方法和应用
CN103842364A (zh) 2011-09-30 2014-06-04 奇尼塔公司 抗病毒化合物
WO2013062987A1 (en) 2011-10-24 2013-05-02 New York University Methods for identifying janus kinase (jak) modulators for therapeutics
US20140256767A1 (en) 2011-10-31 2014-09-11 The Broad Institute, Inc. Direct inhibitors of keap1-nrf2 interaction as antioxidant inflammation modulators
US9012443B2 (en) 2011-12-07 2015-04-21 Amgen Inc. Bicyclic aryl and heteroaryl sodium channel inhibitors
US8940742B2 (en) 2012-04-10 2015-01-27 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
WO2013158928A2 (en) 2012-04-18 2013-10-24 Elcelyx Therapeutics, Inc. Chemosensory receptor ligand-based therapies
US20130281399A1 (en) 2012-04-19 2013-10-24 Rvx Therapeutics Inc. Treatment of diseases by epigenetic regulation
US20130281397A1 (en) 2012-04-19 2013-10-24 Rvx Therapeutics Inc. Treatment of diseases by epigenetic regulation
AU2013258027B2 (en) 2012-05-08 2017-11-30 Merck & Cie 18F-labelled follate/antifolate analogues
US10155987B2 (en) 2012-06-12 2018-12-18 Dana-Farber Cancer Institute, Inc. Methods of predicting resistance to JAK inhibitor therapy
RS58514B1 (sr) 2012-06-13 2019-04-30 Incyte Holdings Corp Supstituisana triciklična jedinjenja kao inhibitori fgfr
EP2865671B1 (en) 2012-06-22 2017-11-01 Sumitomo Chemical Company, Ltd Fused heterocyclic compound
JP6324380B2 (ja) 2012-07-27 2018-05-16 バイオジェン・エムエイ・インコーポレイテッドＢｉｏｇｅｎ ＭＡ Ｉｎｃ． Ｓ１ｐ調節剤および／またはａｔｘ調節剤である化合物
EP2882763B1 (de) 2012-08-07 2018-08-22 Merck Patent GmbH Metallkomplexe
EP2900639B1 (en) 2012-09-27 2017-08-16 Portola Pharmaceuticals, Inc. Bicyclic dihydropyridone kinase inhibitors
FR2996129B1 (fr) 2012-09-28 2014-12-19 Oreal Procede de coloration capillaire mettant en oeuvre au moins un derive d'heterocycle azote, un sel de manganese ou de zinc, du peroxyde d'hydrogene et du (bi)carbonate
EP2916841A1 (en) 2012-11-07 2015-09-16 Novartis AG Combination therapy
US9073878B2 (en) 2012-11-21 2015-07-07 Zenith Epigenetics Corp. Cyclic amines as bromodomain inhibitors
WO2014087165A1 (en) 2012-12-06 2014-06-12 University Of Bath Tankyrase inhibitors
CA2899322A1 (en) 2013-01-29 2014-08-07 Biogen Ma Inc. S1p modulating agents
KR102081281B1 (ko) 2013-02-08 2020-05-28 삼성디스플레이 주식회사 유기 발광 소자
KR102147424B1 (ko) 2013-03-08 2020-08-25 에스에프씨 주식회사 유기발광 화합물 및 이를 포함하는 유기전계발광소자
US9333213B2 (en) 2013-03-15 2016-05-10 Duke University Prochelators as broad-spectrum antimicrobial agents and methods of use
BR112015030578A2 (pt) 2013-06-18 2017-07-25 Novartis Ag combinações farmacêuticas
WO2014204263A1 (en) 2013-06-20 2014-12-24 The Asan Foundation Substituted pyridinone compounds as mek inhibitors
KR101682020B1 (ko) 2013-06-28 2016-12-02 제일모직 주식회사 화합물, 이를 포함하는 유기 광전자 소자 및 표시장치
CN105530938B (zh) 2013-07-05 2019-10-22 Abivax公司 用于治疗由逆转录病毒引起的疾病的化合物
AU2014290108A1 (en) 2013-07-16 2016-02-04 Kineta, Inc. Anti-viral compounds, pharmaceutical compositions, and methods of use thereof
AU2014310371A1 (en) 2013-08-21 2016-03-10 Resverlogix Corp. Compositions and therapeutic methods for accelerated plaque regression
AR097631A1 (es) 2013-09-16 2016-04-06 Bayer Pharma AG Trifluorometilpirimidinonas sustituidas con heterociclos y sus usos
US10407394B2 (en) 2013-10-04 2019-09-10 Merck Patent Gmbh Triarylamine-substituted benzo[H]quinoline-derivatives as materials for electronic devices
ES2750236T3 (es) 2013-12-09 2020-03-25 UCB Biopharma SRL Derivados heteroaromáticos bicíclicos condensados como moduladores de la actividad del TNF
CN104725249B (zh) 2013-12-20 2019-02-12 广东东阳光药业有限公司 苄胺类衍生物及其在药物上的应用
CN104860931A (zh) 2014-02-21 2015-08-26 常州寅盛药业有限公司 丙肝病毒抑制剂及其制药用途
SG11201607973XA (en) 2014-03-24 2016-11-29 Guangdong Zhongsheng Pharmaceutical Co Ltd Quinoline derivatives as smo inhibitors
WO2015168079A1 (en) 2014-04-29 2015-11-05 Infinity Pharmaceuticals, Inc. Pyrimidine or pyridine derivatives useful as pi3k inhibitors
US9902702B2 (en) 2014-07-15 2018-02-27 Bristol-Myers Squibb Company Spirocycloheptanes as inhibitors of rock
JP2017522324A (ja) 2014-07-17 2017-08-10 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ 新規ナフチリジン及びイソキノリンならびにｃｄｋ８／１９阻害剤としてのその使用
CN105461714B (zh) 2014-09-29 2017-11-28 山东轩竹医药科技有限公司 并环类pi3k抑制剂
KR102308118B1 (ko) 2014-10-22 2021-10-01 삼성전자주식회사 축합환 화합물 및 이를 포함한 유기 발광 소자
CN104311426A (zh) 2014-10-27 2015-01-28 厦门大学 芳香硝基乙烯化合物的新用途
CN105732591B (zh) 2014-12-31 2019-10-25 广东东阳光药业有限公司 取代的哌嗪化合物及其使用方法和用途
CA2974784A1 (en) 2015-01-23 2016-07-28 Gvk Biosciences Private Limited Inhibitors of trka kinase
US10227343B2 (en) 2015-01-30 2019-03-12 Vanderbilt University Isoquiniline and napthalene-substituted compounds as mGluR4 allosteric potentiators, compositions, and methods of treating neurological dysfunction
EP3256217A1 (en) 2015-02-11 2017-12-20 Basilea Pharmaceutica International AG Substituted mono- and polyazanaphthalene derivatives and their use
EP3059591A1 (en) 2015-02-23 2016-08-24 Abivax Methods for screening compounds for treating or preventing a viral infection or a virus-related condition
US20180237797A1 (en) 2015-03-30 2018-08-23 Jeffrey Thomas Loh Methods for in vitro production of platelets and compositions and uses thereof
CN105481765A (zh) 2015-04-15 2016-04-13 江苏艾凡生物医药有限公司 一类用于治疗心力衰竭的酰腙类衍生物
KR101904300B1 (ko) 2015-04-15 2018-10-04 삼성에스디아이 주식회사 유기 광전자 소자용 화합물, 이를 포함하는 유기 광전자 소자 및 표시장치
WO2016190847A1 (en) 2015-05-26 2016-12-01 Calitor Sciences, Llc Substituted heteroaryl compounds and methods of use
HK1246593A1 (zh) 2015-06-04 2018-09-14 Kura Oncology, Inc. 用於抑制menin蛋白与mll蛋白的相互作用的方法及组合物
KR20180026459A (ko) 2015-06-18 2018-03-12 세파론, 인코포레이티드 1,4-치환된 피페리딘 유도체
MX2017016325A (es) 2015-06-22 2018-03-02 Ono Pharmaceutical Co Compuesto inhibidor de cinasa de tumor de mama (brk).
WO2017004134A1 (en) 2015-06-29 2017-01-05 Nimbus Iris, Inc. Irak inhibitors and uses thereof
KR102192691B1 (ko) 2015-06-30 2020-12-17 (주)피엔에이치테크 유기발광 화합물 및 이를 포함하는 유기전계발광소자
US9957267B2 (en) 2015-07-01 2018-05-01 Crinetics Pharmaceuticals, Inc. Somatostatin modulators and uses thereof
CR20180168A (es) 2015-08-17 2018-06-27 Lupin Ltd Derivados de heteroarilo como inhibidores de parp
EP3355922A2 (en) 2015-10-02 2018-08-08 Dana Farber Cancer Institute, Inc. Combination therapy of bromodomain inhibitors and checkpoint blockade
WO2017070089A1 (en) 2015-10-19 2017-04-27 Incyte Corporation Heterocyclic compounds as immunomodulators
PE20181198A1 (es) 2015-10-26 2018-07-23 Bayer Cropscience Ag Derivados de heterociclos biciclicos condensados como agentes de control de plagas
US10112955B2 (en) 2015-10-29 2018-10-30 Effector Therapeutics, Inc. Isoindoline, azaisoindoline, dihydroindenone and dihydroazaindenone inhibitors of Mnk1 and Mnk2
AR106515A1 (es) 2015-10-29 2018-01-24 Bayer Cropscience Ag Sililfenoxiheterociclos trisustituidos y análogos
SG11201802961PA (en) 2015-10-30 2018-05-30 Calithera Biosciences Inc Compositions and methods for inhibiting arginase activity
SG10202004618TA (en) 2015-11-19 2020-06-29 Incyte Corp Heterocyclic compounds as immunomodulators
WO2017090002A2 (en) 2015-11-27 2017-06-01 Gvk Biosciences Private Limited Inhibitors of pi3 kinases
EP3390378B1 (en) 2015-12-17 2022-03-30 AlonBio Ltd. Small molecules against cancer
MA44075A (fr) 2015-12-17 2021-05-19 Incyte Corp Dérivés de n-phényl-pyridine-2-carboxamide et leur utilisation en tant que modulateurs des interactions protéine/protéine pd-1/pd-l1
AU2016379372A1 (en) 2015-12-22 2018-08-02 Incyte Corporation Heterocyclic compounds as immunomodulators
EP3445750A4 (en) 2016-04-18 2019-11-27 Celgene Quanticel Research, Inc. THERAPEUTIC COMPOUNDS
AR108396A1 (es) 2016-05-06 2018-08-15 Incyte Corp Compuestos heterocíclicos como inmunomoduladores
JP7014736B2 (ja) 2016-05-24 2022-02-01 ジェネンテック， インコーポレイテッド がんの処置のためのピラゾロピリジン誘導体
WO2017205464A1 (en) 2016-05-26 2017-11-30 Incyte Corporation Heterocyclic compounds as immunomodulators
HUE060256T2 (hu) 2016-06-20 2023-02-28 Incyte Corp Heterociklusos vegyületek mint immunmodulátorok
WO2017223452A1 (en) 2016-06-23 2017-12-28 Dana-Farber Cancer Institute, Inc. Degradation of bromodomain-containing protein 9 (brd9) by conjugation of brd9 inhibitors with e3 ligase ligand and methods of use
EP3481816B1 (en) 2016-07-07 2020-06-24 Bristol-Myers Squibb Company Lactam, cyclic urea and carbamate, and triazolone derivatives as potent and selective rock inhibitors
EP3484866B1 (en) 2016-07-14 2022-09-07 Incyte Corporation Heterocyclic compounds as immunomodulators
GB201615282D0 (en) 2016-09-08 2016-10-26 Univ Bath Tankyrase inhibitors
TW201825465A (zh) 2016-09-23 2018-07-16 美商基利科學股份有限公司 磷脂醯肌醇3-激酶抑制劑
EP3523289A1 (en) 2016-10-07 2019-08-14 Araxes Pharma LLC Heterocyclic compounds as inhibitors of ras and methods of use thereof
MX385576B (es) 2016-11-02 2025-03-18 Janssen Pharmaceutica Nv Derivados de [1,2,4]triazol[1,5-a]pirimidina como inhibidores de pde2
JOP20190144A1 (ar) * 2016-12-16 2019-06-16 Janssen Pharmaceutica Nv إيميدازو بيرولو بيريدين كمثبطات لعائلة jak الخاصة بإنزيمات الكيناز
CN114989205A (zh) 2016-12-22 2022-09-02 卡里塞拉生物科学股份公司 用于抑制精氨酸酶活性的组合物和方法
EP3573954A1 (en) 2017-01-26 2019-12-04 Araxes Pharma LLC Fused bicyclic benzoheteroaromatic compounds and methods of use thereof
JP7327802B2 (ja) 2017-01-26 2023-08-16 アラクセス ファーマ エルエルシー 縮合ヘテロ－ヘテロ二環式化合物およびその使用方法
US20200000099A1 (en) 2017-01-31 2020-01-02 The Regents Of The University Of California Organisms antagonistic to xylella fastidiosa
WO2018204176A1 (en) 2017-05-01 2018-11-08 Sanford Burnham Prebys Medical Discovery Institute Inhibitors of low molecular weight protein tyrosine phosphatase (lmptp) and uses thereof
WO2018204765A1 (en) 2017-05-05 2018-11-08 Pairnomix, Llc Methods of treating epilepsy and kcnq2 related conditions
EP3630836A1 (en) 2017-05-31 2020-04-08 Elstar Therapeutics, Inc. Multispecific molecules that bind to myeloproliferative leukemia (mpl) protein and uses thereof
JP7252908B2 (ja) 2017-06-14 2023-04-05 トレベナ・インコーポレイテッド Ｓ１ｐ１活性を調節するための化合物およびその使用法
WO2018237370A1 (en) 2017-06-23 2018-12-27 Accro Bioscience Inc. Heteroaryl compounds as inhibitors of necrosis, composition and method using the same
WO2019060860A1 (en) 2017-09-25 2019-03-28 Suzhou Yunxuan Yiyao Keji Youxian Gongsi HETEROARYL COMPOUNDS AS INHIBITORS OF CXCR4, COMPOSITION AND METHOD OF USE THEREOF
EP3691639B1 (en) 2017-10-02 2023-11-15 Merck Sharp & Dohme LLC Chromane monobactam compounds for the treatment of bacterial infections
CN109575022B (zh) 2017-12-25 2021-09-21 成都海博锐药业有限公司 一种化合物及其用途
CN109608504B (zh) 2017-12-28 2022-04-05 广州华睿光电材料有限公司 有机金属配合物、聚合物、混合物、组合物和有机电子器件
CN109988109B (zh) 2017-12-29 2020-12-29 广东东阳光药业有限公司 抑制ssao/vap-1的胺类化合物及其用途
EP3735242A4 (en) 2018-01-03 2021-09-01 Merck Sharp & Dohme Corp. METALLO-BETA-LACTAMASE INHIBITORS AND METHOD OF USING THEREOF
CN111892543A (zh) 2018-01-16 2020-11-06 深圳市塔吉瑞生物医药有限公司 用于抑制激酶活性的二苯氨基嘧啶类化合物
US12012394B2 (en) 2018-02-19 2024-06-18 Washington University Alpha-synuclein ligands
US11691967B2 (en) 2018-03-12 2023-07-04 The Board Of Trustees Of The University Of Illinois Antibiotics effective for gram-negative pathogens
WO2019201283A1 (en) 2018-04-20 2019-10-24 Xrad Therapeutics, Inc. Dual atm and dna-pk inhibitors for use in anti-tumor therapy
HRP20241288T1 (hr) 2018-05-04 2024-12-06 Incyte Corporation Čvrsti oblici fgfr inhibitora i postupci za njihovu proizvodnju
WO2019214546A1 (zh) 2018-05-11 2019-11-14 四川科伦博泰生物医药股份有限公司 稠环化合物、其制备方法及用途
CN111484480B (zh) 2019-01-29 2023-08-11 上海翰森生物医药科技有限公司 一种多环类衍生物抑制剂、其制备方法和应用
US20230093099A1 (en) 2019-04-02 2023-03-23 Cullgen (Shanghai), Inc. Compounds and methods of treating cancers
EP4006028B1 (en) 2019-07-26 2025-07-02 Zhuhai Yufan Biotechnologies Co., Ltd Irak4 kinase inhibitor and preparation method therefor
WO2021257863A1 (en) 2020-06-19 2021-12-23 Incyte Corporation Pyrrolotriazine compounds as jak2 v617f inhibitors
US11691971B2 (en) 2020-06-19 2023-07-04 Incyte Corporation Naphthyridinone compounds as JAK2 V617F inhibitors
CR20230057A (es) 2020-07-02 2023-08-15 Incyte Corp Compuestos tríciclicos de urea como inhibidores de jak2 v617f
US11767323B2 (en) 2020-07-02 2023-09-26 Incyte Corporation Tricyclic pyridone compounds as JAK2 V617F inhibitors
US11661422B2 (en) 2020-08-27 2023-05-30 Incyte Corporation Tricyclic urea compounds as JAK2 V617F inhibitors
AU2021346954A1 (en) 2020-09-24 2023-05-25 Auckland Uniservices Limited Novel aminopyridines and their use in treating cancer
US20240124465A1 (en) 2020-12-18 2024-04-18 St. Jude Children's Research Hospital Molecules and methods related to treatment of disorders associated with jak-2 signaling dysfunction
US11919908B2 (en) 2020-12-21 2024-03-05 Incyte Corporation Substituted pyrrolo[2,3-d]pyrimidine compounds as JAK2 V617F inhibitors
AR125273A1 (es) 2021-02-25 2023-07-05 Incyte Corp Lactamas espirocíclicas como inhibidores de jak2 v617f
IL307740A (en) 2021-04-17 2023-12-01 Intellia Therapeutics Inc DNA-dependent protein kinase inhibitors and their compositions and uses
CN117940437A (zh) 2021-09-07 2024-04-26 首药控股(北京)股份有限公司 Dna-pk选择性抑制剂及其制备方法和用途
JP2025505812A (ja) 2022-02-21 2025-02-28 オンクオリティ ファーマシューティカルズ チャイナ リミテッド 化合物及びその用途
AU2023235313A1 (en) 2022-03-17 2024-10-03 Incyte Corporation Tricyclic urea compounds as jak2 v617f inhibitors
US20240190876A1 (en) 2022-10-21 2024-06-13 Incyte Corporation Tricyclic Urea Compounds As JAK2 V617F Inhibitors

Also Published As

Publication number Publication date
LT4175719T (lt) 2025-08-25
SI4175719T1 (sl) 2025-07-31
CR20230057A (es) 2023-08-15
BR112023000047A2 (pt) 2023-03-14
HUE072186T2 (hu) 2025-10-28
CO2023001165A2 (es) 2023-04-27
KR20230057341A (ko) 2023-04-28
MD4175719T2 (ro) 2025-10-31
ES3035284T3 (en) 2025-09-01
US20250320212A1 (en) 2025-10-16
CL2022003834A1 (es) 2023-06-23
ECSP23007180A (es) 2023-05-31
US12187725B2 (en) 2025-01-07
FI4175719T3 (fi) 2025-07-11
US20240150354A1 (en) 2024-05-09
DK4175719T3 (da) 2025-06-23
US11780840B2 (en) 2023-10-10
HRP20250814T1 (hr) 2025-09-12
PE20231739A1 (es) 2023-10-31
WO2022006457A1 (en) 2022-01-06
SMT202500271T1 (it) 2025-09-12
PT4175719T (pt) 2025-06-27
EP4175719A1 (en) 2023-05-10
MA60209B1 (fr) 2025-07-31
EP4175719B1 (en) 2025-05-21
TW202216713A (zh) 2022-05-01
MX2023000056A (es) 2023-04-12
IL299612A (en) 2023-03-01
PL4175719T3 (pl) 2025-09-29
JP7848174B2 (ja) 2026-04-20
RS66978B1 (sr) 2025-07-31
EP4620469A2 (en) 2025-09-24
US20220169649A1 (en) 2022-06-02
JP2023533724A (ja) 2023-08-04
AU2021300429A1 (en) 2023-02-16
EP4620469A3 (en) 2025-10-01
CN116323612A (zh) 2023-06-23

Similar Documents

Publication Publication Date Title
US12187725B2 (en) Tricyclic urea compounds as JAK2 V617F inhibitors
US11958861B2 (en) Spirocyclic lactams as JAK2 V617F inhibitors
US11661422B2 (en) Tricyclic urea compounds as JAK2 V617F inhibitors
WO2022006456A1 (en) Tricyclic pyridone compounds as jak2 v617f inhibitors
US20240376124A1 (en) Macrocyclic Kinase Inhibitors
HK40092779A (en) Tricyclic urea compounds as jak2 v617f inhibitors
HK40092779B (en) Tricyclic urea compounds as jak2 v617f inhibitors
EA053050B1 (ru) Трициклические соединения мочевины в качестве ингибиторов jak2 v617f
US20240317744A1 (en) Bicyclic Ureas As Kinase Inhibitors
US20260062427A1 (en) Bicyclic Ureas As Kinase Inhibitors
US20240300948A1 (en) Heterocyclic Compounds As Kinase Inhibitors
US20250304582A1 (en) Bicyclic Ureas As Kinase Inhibitors
US20260049093A1 (en) Bicyclic Ureas As Kinase Inhibitors
US20250101020A1 (en) Spirocyclic lactam inhibitors
EA053245B1 (ru) Трициклические соединения мочевины в качестве ингибиторов jak2 v617f

Legal Events

Date Code Title Description
MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 4TH ANNIV.) - STANDARD

Year of fee payment: 4

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250625

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250625

D11 Substantive examination requested

Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D11-D117 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION RECEIVED

Effective date: 20250630

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20250630

D00 Search and/or examination requested or commenced

Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D00-D118 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20250905

D11 Substantive examination requested

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D11-D155 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALL REQUIREMENTS FOR EXAMINATION DETERMINED COMPLIANT

Effective date: 20250905

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20250905